A U.K. court invalidated a patent extension for Gilead’s Truvada, potentially allowing for widespread use of generics as a pre-exposure prophylaxis. More: U.K. court invalidates Gilead's Truvada patent extension, allowing PrEP generics Source: fierce
read moreAfter more than 50 years in Arnhem, the Netherlands, Novartis has decided to move its Dutch operations to Amsterdam, the new home of the European Medicines Agency. More: Novartis moving 400 employees to Amsterdam Source: fierce
read moreWhen Bristol-Myers Squibb priced Opdivo in China at half the U.S. cost, industry watchers considered it a benchmark against which future immuno-oncology therapies will measure. Now it appears at least its archenemy, Merck & Co., has taken note for PD-1
read moreAfter Novartis’ Kymriah secured NICE backing in children and young adults, the agency turned the drug away in adults with relapsed or refractory diffuse large B-cell lymphoma after two prior therapies. More: England's cost watchdogs nix Novartis' Kymriah for adults
read morePolisano Pharmaceuticals, once one of the largest drug manufacturers in Romania, is now under the control of rail freight group Grampet after the company upped its stake in the drugmaker from 20% to 74%. More: Romania’s Polisano Pharma now under
read moreNorgine has signed a deal with Shield Therapeutics allowing it to commercialise iron deficiency therapy Feraccru in Europe, Australia and New Zealand. More: Norgine buys rights to sell Shield’s iron deficiency therapy Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals